One Year Follow-Up of Children and Adolescents With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With Rituximab
| Autor: | Mignon L. Loh, Hadi Sawaf, Henry A. Feldman, Adonis Lorenzana, James B. Bussel, George R. Buchanan, Bertil Glader, Thomas A. Olson, Brigitta U. Mueller, Theodore B. Moore, Zora R. Rogers, Carolyn M. Bennett, Stephen A. Feig, Ellis J. Neufeld, William C. Mentzer, Thomas C. Abshire, Donald H. Mahoney, Maggie McCarthy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty One year follow up Adolescent Hemorrhage Article Antibodies Monoclonal Murine-Derived Immune system Recurrence Internal medicine medicine Humans Platelet Prospective cohort study Child Purpura Thrombocytopenic Idiopathic business.industry Platelet Count Remission Induction Antibodies Monoclonal Infant Hematology medicine.disease Thrombocytopenic purpura Immune thrombocytopenia Surgery Clinical trial Oncology Child Preschool Pediatrics Perinatology and Child Health Chronic Disease Rituximab Female business medicine.drug Follow-Up Studies |
| Popis: | Background We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm3 within the first 12 weeks. These patients were followed for the next year. Methods Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results Eight of the 11 initial responders maintained a platelet count over 150,000/mm3 without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm3 without the need for further intervention. Conclusions Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm3 or higher in 11 of 36 patients (31%). Pediatr Blood Cancer 2009;52:259–262. © 2008 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|